Cyproterone acetate: is it hepato- or genotoxic?

Area of Science:

• Hepatology
• Toxicology
• Oncology

Background:

• Preclinical safety assessments of cyproterone acetate (CPA) have historically focused on liver tumorigenesis.
• Recent in vitro studies suggest CPA may form DNA adducts and enhance DNA repair synthesis, raising questions about mutagenic potential.
• Dose-related hepatic toxicity has been reported with prolonged CPA use.

Purpose of the Study:

• To evaluate the risk of liver tumorigenesis associated with cyproterone acetate (CPA) treatment.
• To assess the clinical relevance of in vitro findings regarding CPA's potential genotoxicity.
• To investigate the correlation between long-term CPA use and liver enzyme elevations or hepatocellular carcinoma.

Main Methods:

• Review of preclinical tumorigenicity studies.
• Analysis of in vitro studies on DNA adduct formation and repair synthesis.
• Active surveillance and multicenter surveillance studies of patients undergoing long-term CPA treatment.

Main Results:

• Preclinical studies revealed no mutagenic potential for CPA.
• The role of CPA-induced adducts and DNA synthesis in mutagenesis remains unclear.
• No correlation was found between CPA treatment duration and liver enzyme elevations in an active surveillance study.
• A multicenter study of 2506 patients on long-term CPA found no cases of hepatocellular carcinoma.

Conclusions:

• Current findings do not support an elevated risk of hepatocellular carcinoma with CPA treatment.
• No evidence suggests an increased risk of proliferative liver changes due to CPA therapy.
• The clinical significance of in vitro genotoxicity findings for CPA in humans requires further clarification.